Fundraising Fox
RA Capital
Venture capitalActively deployingBoston · Seed–Late Stage · 266 people tracked
Also known as RA CAPITAL MANAGEMENT, LP
Find your way into RA Capital
Sign up to see every warm intro you have to RA Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the RA Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Since 2004, RA Capital has focused on turning breakthrough science into durable companies across healthcare and planetary health. Its investment decisions are evidence-based and science-led, originating conviction from TechAtlas, the firm's proprietary knowledge engine. RA Capital provides multi-stage capital from seed funding through IPOs and follow-on financings, aiming to supply the right capital at the right milestone. Beyond writing checks, the firm takes a hands-on approach, developing custom platforms and services and co-creating companies. Its Raven incubator has originated and built dozens of healthcare companies since 2018, while the firm also runs a Blackbird clinical development accelerator, working closely with founders to translate bold ideas into enterprises.
Source: firm website, verified Sep 29, 2026.
Team · 266 people
from the firm's website & public directories
Founder mafia
The RA Capital mafia →10 people who came through RA Capital went on to found or lead other companies.
What they invest in
from 284 of 373 portfolio companiesBiotech ×235Healthtech ×152Medical Devices ×93Deep Tech ×37Digital Health ×34AI & Machine Learning ×33Cleantech ×9Hardware ×8
HQs:United States×215United Kingdom×4Denmark×3Canada×2Switzerland×2China×2
Who they back
founder profiles across 125 portfolio companiesFounding team size:solo founder×512 founders×393 founders×204+ founders×15
Where their founders studiedfrom 98 founders with education data
Massachusetts Institute of Technology ×8University of California, Berkeley ×8Harvard Business School ×7Stanford University ×5The Johns Hopkins University School of Medicine ×5Harvard Medical School ×4Cornell ×3Dartmouth College ×3
What their founders studiedfrom 96 founders with field-of-study data
Life Sciences ×41Engineering ×20Medicine ×15Business & Management ×12Computer Science ×12Chemistry ×10Finance & Accounting ×10Physics ×6
Where their founders worked beforefrom 109 founders with career history
10x Genomics ×5Johnson & Johnson ×5MPM BioImpact ×5Harvard Medical School ×4University of California, San Francisco ×4Celsius Therapeutics ×2Chiron Corporation ×2ClarVista Medical ×2
Accelerator rootsportfolio companies that came through a program
55 founders hold a PhD · 17 hold an MBA (of 100 with degree data)
Investments · 373 tracked
founders shown can be your intro pathBy year:2026 · 302025 · 242024 · 232023 · 72022 · 142021 · 252020 · 142019 · 102018 · 92017 · 42016 · 52015 · 8176 dated
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US
Riley Ennis(Founder)inCharles Roberts(Founder)inGabriel Otte(Founder)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)
Co-investorsAgent CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management CompanyAverin Capital+15 more
Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs.
BiotechHealthtechMedical Devices
Greg(Co-founder & Senior Vice President of Discovery Research)Mark(Co-founder & Senior Vice President of Medicinal Chemistry)Mike(President & CEO)Charlotte(Chief Medical Officer)Elena(Chief Financial Officer)Caroline(Chief Business Officer)
Co-investorsAtlas VentureOrbiMedViking Global
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.
BiotechHealthtechRadnor, US
Eric Warren(Chief Commercial Officer)inAlex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)
BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)Olivier Litzka(Director)in
Board seatDerek DiRocco· per SEC Form D
Co-investorsAndera PartnersHBM Healthcare InvestmentsHBM PartnersSamsara BioCapitalSR One Capital ManagementYsios Capital+3 more
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.
BiotechCambridge, US
Ankit Mahadevia(Executive Officer, Director)inStephen Garbacz(Executive Officer)inEsther Rajavelu(Director, President, Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer)in
BoardJean-Francois Formela(Director)inCasper Breum(Director)
Board seatReza Halse· per SEC Form D
Co-investorsGV (Google Ventures)HEALTHCARE ROYALTY PARTNERSMRL Ventures FundOUP (Osage University Partners)AlphabetAtlas Venture+1 more
Wave Life Sciences develops RNA-targeting therapeutics using RNA-editing modalities and chemistry to treat rare and common diseases, with a clinical pipeline addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity.
BiotechHealthtechLongevitySingapore, US
Takeshi Wada(Director)inGregory L. Verdine(Director)Paul B. Bolno, M.D.(Executive Officer, Director)inPaul Bolno, MD, MBA(President and Chief Executive Officer, Wave Life Sciences)
BoardKen Takanashi(Director)
Board seatPeter Kolchinsky· per SEC Form D
Co-investorsForesite CapitalAescap Life Sciences
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.
BiotechHealthtechMedical DevicesWayne, US
Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)inJoseph Monahan(Executive Officer)inHugh Davis(Executive Officer, Director)inJames Loerop(Executive Officer)
Co-investorsAisling CapitalAPERTURE Venture PartnersF-Prime CapitalForesite CapitalSofinnova VenturesSofinnova Venture Partners+1 more
Adagio Medical develops and commercializes catheter-based cardiac ablation devices using proprietary Ultra-Low Temperature Ablation (ULTA) technology to treat ventricular tachycardia and other cardiac arrhythmias.
HealthtechLaguna Hills, US
Olav Bergheim(Executive Officer, Director)Andrew Wade(Executive Officer)Hugh Neuharth(Executive Officer)Todd Usen(Chief Executive Officer and Director)inDeborah Kaster(Chief Financial Officer and Chief Business Officer)in
BoardMichael Zhao(Director)
Adagio Medical Holdings develops and commercializes catheter-based ablation devices using proprietary Ultra-Low Temperature Ablation technology to treat ventricular tachycardia, a life-threatening abnormal heart rhythm, primarily in patients with structural heart disease.
HealthtechLaguna Hills, US
Todd Usen(Executive Officer, Director)inDeborah Kaster(Executive Officer)in
BoardKeyvan Mirsaeedi-Farahani(Director)Orly Mishan(Director)James L. Cox(Director)Timothy P. Moran(Director)
Invivyd develops monoclonal antibody therapies to prevent and treat serious viral infections, beginning with COVID-19 and expanding to respiratory syncytial virus and measles.
BiotechWaltham, US
Tillman U. Gerngross(Executive Officer, Director)Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)inEllie Hershberger(Executive Officer)
Co-investorsGV (Google Ventures)Fidelity InvestmentsForesite CapitalMithril Capital ManagementOmega FundsOrbiMed+3 more
Spyre Therapeutics develops monoclonal antibodies with extended half-lives targeting inflammatory bowel disease and rheumatic conditions including rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
BiotechAustin, US
David G. Lowe(Executive Officer, Director)George Georgiou(Director)Charles N. York(Executive Officer)inCameron Turtle(Chief Executive Officer and Director)
BoardHenry Skinner(Director)Armen Shanafelt(Director)
Co-investorsAisling Capital
Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL.
BiotechHealthtechLexington, US
Garo Armen(Chairman & CEO, Co-founder)Ozer Baysal(Executive Officer)Robert Stein(Executive Officer)Christine Klaskin(Executive Officer)inKaren Valentine(Executive Officer)Steven O'Day(Chief Medical Officer)in
Co-investorsAdvent Life SciencesGrazia Equity GmbHHEALTHCARE ROYALTY PARTNERSOberland CapitalCommodore CapitalInvus+1 more
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPaul L. Feldman(Chief Scientific Officer)in
Co-investorsAndreessen HorowitzEcoR1 CapitalMPM BioImpactMRL Ventures FundPappas CapitalTCG Crossover+5 more
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders.
BiotechHealthtechMenlo Park, US
Joseph S. Zakrzewski(Co-Founder & Director)Eric Easom(Co-Founder, President & CEO)inGeorge H. Talbot(Co-Founder & Senior Clinical Advisor)Michael R.K. (Dickon) Alley(Co-Founder, SVP Research Fellow, Head of Biology)Sanjay Chanda(Chief Development Officer)inLucy O. Day(Chief Financial Officer)in
Co-investorsAdjuvant CapitalBioRock VenturesFlucas VenturesMountain Group CapitalBiotechnology Value FundHatteras Venture Partners
Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
BiotechHealthtechMedical Devices
Michael Henderson(Chief Executive Officer and Director)in
Co-investorsAccess BiotechnologyWellington ManagementBlackstone Life SciencesPerceptive Xontogeny VentureRTW Investments L.P.Venrock Healthcare Capital Partners
Arcutis is a biopharmaceutical company focused on dermatology, developing treatments for immune-mediated skin diseases such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.
BiotechHealthtechMedical DevicesWestlake Village, US
Todd Franklin Watanabe(Executive Officer, Director)Alexander Asam(Director)Ricky Sun(Director)
BoardPatrick Heron(Director)inDaniel Estes(Director)inJonathan Silverstein(Director)
Co-investorsBain Capital Life SciencesFrazier Life Sciences
Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.
BiotechHealthtechNew Haven, US
Sean Cassidy(Executive Officer)inManuel Litchman(Executive Officer, Director)inRandy Teel(President and Chief Executive Officer; Director)inCraig Crews(Founder)
BoardStephen Squinto(Director)inLiam Ratcliffe(Director)in
Co-investors5AM VenturesAccess BiotechnologyCanaan PartnersConnecticut InnovationsNextech InvestSolasta Ventures+2 more
Atea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV).
BiotechHealthtechBoston, US
Jean-Pierre Sommadossi, Ph.D.(Executive Officer, Director)Jean-Pierre Sommadossi(President, CEO and Chairman of the Board)inAndrea Corcoran(Chief Financial Officer, Executive Vice President, Legal, and Secretary)Janet Hammond(Chief Development Officer)inMaria Arantxa Horga(Chief Medical Officer)inJohn Vavricka(Chief Commercial Officer)in
Co-investorsATEM Capital FundBain Capital Life Sciences
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors.
Ivan Hyep(Chief Financial Officer and Treasurer)inLara Meisner(Chief Legal Officer, Compliance Officer and Corporate Secretary)inDavid Raben(Chief Medical Officer)in
Co-investorsAisling CapitalEight Roads VenturesF-Prime CapitalForesite CapitalPremji InvestRed Tree Venture+6 more
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.
BiotechHealthtechLongevityRichmond, US
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Founder)inEric Morgen(Founder)inDov Goldstein(Executive Officer)in
BoardPatrick Enright(Director)in
Co-investorsAndreessen HorowitzElad GilFelicis VenturesGreen Sands EquityIA Seed VenturesLongitude Capital+19 more
Biohaven is a pharmaceutical company that discovers, develops, and commercializes medications for neurological and neuropsychiatric diseases, including epilepsy, pain, mood disorders, OCD, spinocerebellar ataxia, and spinal muscular atrophy.
BiotechHealthtechMedical DevicesConnecticut, US
Vlad Coric, M.D.(Chairman & Chief Executive Officer)in
Co-investorsConnecticut InnovationsOberland CapitalSixth StreetBlackRock
Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma.
Elizabeth Buck(Chief Scientific Officer)inBrent Hatzis-Schoch(Chief Operating Officer and General Counsel)inSergey Yurasov(Chief Medical Officer)inMelanie Morrison(Chief Development Officer)
Co-investorsLAVLilly Asia VenturesNew Enterprise Associates (NEA)Nextech InvestNSG VenturesVersant Ventures+4 more
Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.
BiotechHealthtechMedical DevicesSan Francisco, US
Dr. Edgar G. Engleman(Founder)
Co-investorsPfizer Venture InvestmentsPivotal Life SciencesSamsara BioCapitalSofinnova VenturesVivo CapitalNan Fung Life Sciences+3 more
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Zachary D. Hornby(Executive Officer, Director)inRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in
BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)in
Co-investorsARCH Venture PartnersNextech InvestWellington ManagementAlexandriaCity Hill VenturesSectoral Asset Management+3 more
C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.
BiotechCambridge, US
Kenneth C. Anderson(Director)Andrew J. Hirsch(Director and Chief Executive Officer)in
BoardMarc Cohen(Executive Officer, Director)inJason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)
Co-investors3E Bioventures CapitalBain Capital Life SciencesNextech InvestCobro Ventures
Century Therapeutics develops allogeneic, iPSC-derived cell therapies using gene editing and protein engineering for autoimmune diseases including type 1 diabetes and cancer.
AI & Machine LearningBiotechHealthtechMedical DevicesPhiladelphia, US
Osvaldo Flores, Ph.D.(Executive Officer, Director)Douglas Carr(Executive Officer)inBrent Pfeiffenberger(President and Chief Executive Officer)inGregory Russotti(Chief Technology and Manufacturing Officer)Chad Cowan(Chief Scientific Officer)in
BoardToshikazu Ban(Director)
Co-investorsLifeSci Venture PartnersCasdin CapitalVersant Ventures
Ceribell is a medical technology company that develops products for detecting and monitoring seizures, including EEG-based diagnostic systems.
AI & Machine LearningDigital HealthHealthtechMedical DevicesSunnyvale, US
Josef Parvizi(Director)inXingjuan (Jane) Chao(President, CEO, Co-Founder & Director)inScott Blumberg(Executive Officer)inJoseph Taylor(Director)Raymond Woo(Executive Officer)David Stoffel(Executive Officer)
Co-investorsLongitude CapitalRed Tree VentureShangBay Capital LLCThe Rise Fund
CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.
BiotechHealthtechMedical Devices
Arthur Kuan(Chairman and Chief Executive Officer)in
Co-investorsDecheng CapitalForesite CapitalLongitude CapitalPalm Drive CapitalTCG CrossoverACORN BIOVENTURES+3 more
Climb Bio develops monoclonal antibody therapies for immune-mediated diseases, advancing clinical-stage candidates such as budoprutug for conditions including immune thrombocytopenia.
BiotechHealthtech
Andrew Levin(Director)Aoife Brennan, MB, ChB(President and Chief Executive Officer)Perrin Wilson, PhD(Chief Business Officer)Susan Altschuller, PhD, MBA(Chief Financial Officer)Edgar Charles, MD(Chief Medical Officer)Ashley Jones(Senior Vice President, People & Workforce Strategy)in
Co-investorsLifeArc Ventures
Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions.
BiotechCanton, US
Michael Heffernan(Executive Officer, Director)inPaul Brannelly(Executive Officer)inVikram Karnani(President and Chief Executive Officer, and Director)in
BoardEran Nadav(Director)John Freund(Director)Patrick Heron(Director)in
Co-investorsAPERTURE Venture PartnersEcoR1 CapitalFrazier Life SciencesLongitude CapitalBoston Millennia Partners
Connect Biopharma is a clinical-stage biopharmaceutical company developing antibody-based therapies targeting inflammatory diseases such as atopic dermatitis and asthma.
BiotechHealthtechSan Diego, US
Barry D. Quart(Chief Executive Officer and Director)inDavid Szekeres(President)inKimberly J. Manhard(Executive Vice President, Chief Development Officer)in
Co-investorsCo-Win Ventures
Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.
BiotechSan Diego, US
Richard Scott Struthers(Executive Officer, Director)Stephen Betz(Chief Scientific Officer)inR. Scott Struthers(President, Chief Executive Officer and Director)inTobin Schilke(Chief Financial Officer)inIsabel Kalofonos(Chief Commercial Officer)inYunFei Zhu(Executive Officer)
Co-investors5AM VenturesForesite CapitalOrbiMedVivo Capital
Cytek Biosciences develops high-parametric analytical instruments and software that enable scientists at pharmaceutical companies, contract research organizations, and academic institutions to generate and analyze biological datasets.
BiotechDeep TechHardwareHealthtechMedical DevicesBellevue, US
Wenbin Jiang, Ph.D.(CEO and Chairman of the Board; co-founder)Wenbin Jiang(Executive Officer, Director)inMing Yan, Ph.D.(Chief Technology Officer; co-founder)Ming Yan(Executive Officer, Director)inJiecheng Zhang(Director)Allen Poirson(Director)
Co-investors3E Bioventures CapitalF-Prime CapitalNorthern Light Venture Capital
Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.
BiotechCopenhagen, US
Garrett Winslow(Executive Officer)inLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)
Co-investorsAccess BiotechnologyViking GlobalAndreessen HorowitzBAM ElevateBay City CapitalCommodore Capital+8 more
Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform.
BiotechMedical DevicesSolana Beach, US
Pratik Shah, Ph.D.(Executive Officer, Director)Aseem Z. Ansari, Ph.D.(Director)Sean Jeffries, Ph.D.(Executive Officer)
BoardSimeon George, M.D.(Director)Stella Xu, Ph.D.(Director)Rodney Lappe, Ph.D.(Director)
Co-investorsAvoro Capital AdvisorsQuan CapitalSR One Capital ManagementWellington ManagementWestRiver Group
CervoMed is a clinical-stage pharmaceutical/biotech company focused on developing drug treatments, progressing candidates from early- to late-stage development toward commercialization.
BiotechHealthtechMedical DevicesCharlottesville, US
John L. Gainer(Executive Officer, Director)inDavid G. Kalergis(Executive Officer, Director)inDavid R. Jones(Executive Officer)inBen L. Shealy(Executive Officer)John Moynahan(Executive Officer)Stephen Simes(Executive Officer, Director)
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.
BiotechMedical DevicesWaltham, US
Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)inOxana Beskrovnaya, Ph.D.(Executive Officer)John G. Cox(President and Chief Executive Officer)in
Co-investorsAtlas VentureMPM BioImpactVida VenturesWellington ManagementForbionHercules Capital, Inc.
Eliem Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies targeting immune-mediated diseases, with budoprutug, an anti-CD19 antibody designed to deplete B cells in conditions including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy and related B-cell mediated diseases.
BiotechWilmington, US
Valerie Morisset(Executive Officer)inErin Lavelle(Executive Officer)inRobert Azelby(Executive Officer, Director)James Bucher(Executive Officer)Leone Patterson(Director)
BoardAdam Rosenberg(Director)
Co-investorsManta Ray VenturesAccess BiotechnologyACORN BIOVENTURESIntermediate Capital GroupLifeArc Ventures
Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.
BiotechHealthtechBoulder, US
Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHelen Collins(Chief Medical Officer)inBen Hohl(Chief Financial Officer and Head of Corporate Development)in
Co-investors5AM VenturesOrbiMedPfizer Venture InvestmentsRoche Venture FundARCH Venture PartnersBay City Capital+2 more
A pharmaceutical company whose executive team emphasizes innovation and patient care.
BiotechDigital HealthMental Health
Co-investorsForesite Capital
Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAccess BiotechnologyAvoro Capital AdvisorsHealthCapNovo HoldingsSofinnova Partners
Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.
BiotechCambridge, US
James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)
BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)
Co-investorsBay City CapitalNew Enterprise Associates (NEA)Pfizer Venture InvestmentsAlexandriaArix BioscienceJMI Equity+3 more
Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering.
BiotechHealthtech
Co-investorsBain Capital Life SciencesForesite CapitalMRL Ventures FundPremji InvestGV (Google Ventures)Mithril Capital Management+2 more
A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.
BiotechArlington, US
Justin Hanes(Director)inKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)inTodd Bazemore(Executive Officer)inMark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in
Co-investorsLongitude CapitalSR One Capital ManagementWellington ManagementYsios CapitalAtlas VentureLux Capital+1 more
Monopar Therapeutics is a clinical-stage biotechnology company developing radiopharmaceuticals for oncology and a treatment for Wilson Disease, a rare genetic disorder.
BiotechHealthtechMedical DevicesLake Forest, US
Chandler D. Robinson(Executive Officer, Director, Promoter)inChristopher M. Starr(Executive Officer, Director)Andrew P. Mazar(Executive Officer, Director)
BoardMichael J. Brown(Director)
Co-investorsJanus Henderson Investors
Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.
BiotechDigital HealthHealthtechMedical Devices
Matthew Rabinowitz(Co-founder & Executive Chairman)inJonathan Sheena(Founder)inSteven Chapman(Chief Executive Officer & President)
Co-investorsBain Capital Life SciencesCheyenne VenturesClaremont Creek VenturesForesite CapitalHarmony PartnersHBM Healthcare Investments+4 more
Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.
BiotechHealthtechSouth San Francisco, US
Paul Hastings(Executive Officer, Director)inPaul H.inMatthew Plunkett(Executive Officer)in
BoardMichael Dybbs(Director)Jill Carroll(Director)inTiba Aynechi(Director)in
Co-investorsNew Enterprise Associates (NEA)Samsara BioCapitalSR One Capital ManagementAmgen VenturesLogosNorwest Venture Partners+1 more
Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.
BiotechHealthtechSan Francisco, US
Cyrus L. Harmon, Ph.D.(Director)Cyrus L. Harmon(Director)inDavid C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)inShane Kovacs(Executive Officer)in
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesForesite CapitalLightspeed Venture PartnersWellington ManagementBiotechnology Value Fund+2 more
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)+9 more
.png)
Peloton develops connected fitness equipment and a digital fitness app that delivers personalized workout classes and training guidance to home exercisers.
ConsumerHardwareWellness & FitnessNew York, US
Graham Stanton(Founder)John Foley(Founder)inHisao Kushi(Founder)inPeter Stern(Chief Executive Officer and President)inElizabeth Coddington(Chief Financial Officer)Nick Caldwell(Chief Product Officer)in
Co-investorsAnsa CapitalBlue CollectiveBullishCade VenturesCoatue ManagementFELIX CAPITAL+22 more
PepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.
AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US
James McArthur(Executive Officer, Director)inNoel P. Donnelly(Chief Financial Officer)inJoseph D. Vittiglio(Chief Business & Legal Officer and Secretary)inKasra Kasraian(Chief Technical Officer)in
BoardRamin Farzaneh-Far(Director)inJoshua Resnick(Director)
Co-investorsOxford Science EnterprisesViking Global
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)inDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)inMichael Amoroso(President, Chief Executive Officer)in
BoardROBERT ADELMAN(Director)
Co-investorsage1Agent CapitalAliment CapitalBrace PharmaF-Prime CapitalOCV Partners+6 more
Protagonist is a company that emphasizes a diverse and inclusive corporate culture as central to its innovation, with stated goals of creating wins for its organization and for patients.
BiotechHealthtechMilpitas, US
Dinesh V. Patel, PhD(Executive Officer, Director)Dinesh Patel(President & Chief Executive Officer)
BoardAsish K. Xavier, Ph.D.(Director)Michael Panaccio, Ph.D.(Director)Armen Shanafelt, Ph.D.(Director)Paul F. Truex(Director)
Co-investorsAisling CapitalCanaan PartnersJJDCJohnson & Johnson Innovation – JJDCLilly VenturesStarfish Ventures
Prothena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins.
BiotechDun Laoghaire, Co. Dublin, US
Tran B. Nguyen(Executive Officer)Arthur W. Homan(Executive Officer)Karin L. Walker(Executive Officer)inTara Nickerson, Ph.D.(Executive Officer)Wagner M. Zago, Ph.D.(Executive Officer)Carol D. Karp(Executive Officer)in
Co-investorsSofinnova VenturesInvescoWellington Management
Pyxis Oncology develops antibody-drug conjugates and immunotherapies targeting difficult-to-treat cancers to improve patient outcomes.
BiotechDigital HealthHealthtechMedical DevicesBoston, US
Thomas Civik(Interim Chief Executive Officer, Director)
BoardDavid Steinberg(Executive Officer, Director)inChristoph Westphal(Director)Geeta Vemuri(Director)inJak Knowles(Director)John Flavin(Director)
Co-investorsAgent CapitalLifeSci Venture PartnersLongwood FundPfizer Venture InvestmentsTrans-Pacific Technology FundRTW Investments L.P.
Rani Therapeutics develops oral drug delivery technology using robotic capsules to replace injectable biotherapeutics, addressing the challenge of delivering biologics through the gastrointestinal tract without needles.
BiotechDigital HealthHealthtechMedical DevicesSan Jose, US
Mir Hashim(Executive Officer, Director)inTalat Imran(Chief Executive Officer)in
BoardMir Imran(Founder)Andrew Farquharson(Director)in
Co-investorsGV (Google Ventures)InCube VenturesVHM
Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for biologics and drugs, primarily through its proprietary RaniPill capsule platform, which comes in two configurations (RaniPill GO for up to 3 mg microtablet doses and RaniPill HC for up to 200µL liquid doses).
BiotechSan Jose, US
Talat Imran(Executive Officer, Director)inSvai Sanford(Executive Officer)inMir Hashim(Executive Officer)in
BoardAbraham Bassan(Director)Vasudev Bailey, M.D.(Director)Mir Imran(Director)
Co-investorsInCube Ventures
Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.
BiotechHealthtechNew York, US
Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)inEliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)
Co-investorsBioAdvanceBAM ElevateBraidwellCommodore CapitalJanus Henderson InvestorsOrbiMed+2 more
RxSight is an ophthalmic medical technology company that developed the Light Adjustable Lens (LAL), an intraocular lens that can be customized after cataract surgery to optimize a patient's vision.
HardwareHealthtechMedical DevicesPasadena, US
Robert H. Grubbs(Director)Daniel M. Schwartz(Director)D. Verne Sharma(Executive Officer, Director)Richard Drinkward(Executive Officer)inRon Kurtz(Chief Medical Officer (former President & CEO))Mark Wilterding(Chief Financial Officer)in
Co-investorsFlying L PartnersForesite CapitalH.I.G. CapitalH.I.G. HealthBridge PartnersLongitude CapitalVisionary Ventures+2 more
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder)inJennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)Brett Staahl(Founder)
Co-investorsAndreessen HorowitzOrbiMedAvoro Capital AdvisorsMenlo VenturesWellington Management
SCYNEXIS is a biopharmaceutical company focused on developing drug therapies for severe rare diseases, including anti-infective and antifungal treatments.
BiotechMedical DevicesDurham, US
Yves J. Ribeill(Executive Officer, Director)inCharles F. Osborne, Jr.(Executive Officer)Brian Schwab(Executive Officer)inDavid Angulo(President & Chief Executive Officer)inEric Sukenick(General Counsel)Sanjay Subramanian(Chief Financial Officer)
Co-investorsDecheng CapitalForesite CapitalDeerfield Management Company
Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Matthew Henn(President and Chief Scientific Officer)inJohn Aunins(Executive Officer)inEric D. Shaff(Executive Officer)inDavid Cook(Executive Officer)inRoger J. Pomerantz(Executive Officer, Director)inRichard N. Kender(Executive Chair and Interim Chief Executive Officer)
Co-investorsFlagship PioneeringSofinnova VenturesFidelity Investments
Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy.
BiotechHealthtechCharlestown, US
Ilan Ganot(Co-Founder and Director)inStephen DiPalma(Executive Officer)Carl Morris(Executive Officer)inAlexander Cumbo(President, Chief Executive Officer and Director)Martin Freed(Director)inPaul Herizch(Executive Officer)
Co-investorsBain Capital Life SciencesForesite CapitalBain Capital
SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation.
BiotechHealthtechMedical DevicesAliso Viejo, US
Glenn Sussman(Co-founder)inMalik Y. Kahook(Co-founder)inPatrick Mooney(CEO)
BoardJake Merrill(Director)Geoff Pardo(Director)Bilal Khan(Director)
Co-investorsNew Enterprise Associates (NEA)Samsara BioCapitalSands Capital VenturesVensana Capital
Vaxcyte is a biotech company developing vaccines to treat or prevent serious infectious diseases.
BiotechDeep TechHealthtechSouth San Francisco, US
Grant Pickering(Chief Executive Officer, Director and Co-Founder)Jeff Fairman(Vice President of Research and Co-Founder)Ashish Khanna(Executive Officer)
BoardTracy Saxton(Director)William Newell(Director)Kurt von Emster(Director)in
Co-investorsAbingworthCTI Life Sciences Fund L.P.Foresite CapitalFrazier Life SciencesJanus Henderson InvestorsLongitude Capital+4 more
Tenaya Therapeutics is a biotechnology company focused on discovering and developing therapies for heart disease.
BiotechHealthtechSouth San Francisco, US
Deepak Srivastava, M.D.(Scientific Founder)inEric Olson, Ph.D.(Scientific Founder)Bruce R. Conklin, M.D.(Scientific Founder)inSheng Ding, Ph.D.(Scientific Founder)Saptarsi Haldar, M.D.(Scientific Founder)inEric Hyllengren(Chief Financial Officer)in
Co-investorsGV (Google Ventures)The Column GroupvenBio Partners
Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers.
BiotechHealthtechCarlsbad, US
Todd Harris, Ph.D.(Executive Officer, Director)Hiroomi Tada, M.D., Ph.D.(Executive Officer)Daniel Bensen(Executive Officer)inAlan Fuhrman(Executive Officer)inTodd Harris(President, Chief Executive Officer and Director)inBhavesh Ashar(Chief Operating Officer)in
Co-investorsAlta PartnersBioBritNextech InvestCanaan Partners
Vaxcyte is a clinical-stage biotechnology company developing vaccines to prevent or treat bacterial infectious diseases, including pneumococcal conjugate vaccine candidates.
BiotechHealthtech
Grant Pickering(Chief Executive Officer, Director and Co-Founder)inJeff Fairman(Vice President of Research and Co-Founder)
Co-investorsBioRock VenturesCTI Life Sciences Fund L.P.Foresite CapitalFrazier Life SciencesLongitude CapitalPivotal Life Sciences+3 more
Vor Biopharma is a biopharmaceutical company.
BiotechCambridge, US
Nathan Jorgensen(Executive Officer)Amy Mendel(Executive Officer)Robert Ang(Executive Officer, Director)Jean-Paul Kress(President, Chief Executive Officer and Chairman of the Board)in
BoardKush Parmar(Director)inJoshua Resnick(Director)
Co-investors5AM VenturesOUP (Osage University Partners)PureTech Health
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)
Co-investorsBain Capital Life SciencesBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRiverVest Venture Partners+9 more
Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.
BiotechHealthtechMedical DevicesAustin, US
Shanshan Xu(Founder & Chief Executive Officer)inHelmut Jeggle(Co-Founder)inThang Ho(Chief Development Officer)inCrystal MacKay(Chief Operating Officer)in
Board seatDerek DiRocco· per SEC Form D
Co-investorsINCE CapitalSalviaBiotechnology Value FundJanus Henderson InvestorsREDMILE
Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.
BiotechDeep TechMedical DevicesSeattle, US
Marc Lajoie(Founder)inScott Boyken(Founder)inStanley Riddell(Co-Founder and Scientific Advisor)Aaron Foster(Executive Officer)inCharity Scripture(Executive Officer)inEric Soller(Executive Officer)in
Board seatJake Simson· per SEC Form D
Co-investorsArtis VenturesAbstract VenturesATEL VenturesAtinum Investment Co. Ltd.Civilization Ventures Management, LlcMana Ventures+8 more
Solstice Oncology is a clinical-stage immuno-oncology company developing porustobart, a second-generation engineered CTLA-4 antibody given with anti–PD-1 therapy in the neoadjuvant (pre-surgery) setting to treat early-stage cancers.
BiotechHealthtechBoston, US
David Feltquate(Chief Medical Officer)inMaiken Keson-Brookes(Chief Operating Officer & General Counsel)CAROLINE LOEW(Executive Officer, Director, Promoter)Caroline J. Loew(President & Chief Executive Officer)
BoardJULIE GRANT(Director)in
Board seatEmily MinkowAndrew Levin· per SEC Form D
Co-investorsForbionCanaan Partners
Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients.
BiotechHealthtechCambridge, US
Aaron Ring(Co-founder)inAashish Manglik(Co-founder)inJeff Landau(Chief Executive Officer)inRoland Gendron(Chief Business Officer)inMichelle Zhang(Chief Scientific Officer)in
BoardVineeta Agarwala(Director)in
Board seatDerek DiRocco· per SEC Form D
Co-investorsAndreessen HorowitzGV (Google Ventures)Magnetic VenturesOMX VenturesAxial VCLoLa Capital Partners+1 more
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Founder)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)Samsara BioCapitalSanofi VenturesMass General Brigham VenturesREDMILE+9 more
Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology.
BiotechHealthtechMedical Devices
Jack Elands(Founder & CEO)inXavier Preville(Co-founder, VP & Head of Research & Preclinical Development)inJan H.M. Schellens(Chief Medical Officer)inThierry Menguy(VP & Head of CMC Operations)inJaime Arango(Chief Financial Officer)inPaul Jackson(Chief Operating Officer)in
Co-investorsaMoonBpifranceAndera PartnersAngelini VenturesKurma PartnersPontifax Venture Capital+1 more
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.
AI & Machine LearningBiotechDeep TechHealthtech
Jane Osbourn(Founder)Young Kwon(Founder)
Co-investorsSV Health InvestorsDCVC BioDementia Discovery FundLightstone VenturesOno Venture Investment, Inc.British Business Bank+3 more
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.
AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH
Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)inLuigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in
Co-investorsAvego BioScience CapitalBioMedPartnersFrazier Life SciencesJeito CapitalLongitude CapitalNovo Holdings+5 more
Atavistik Bio develops selective allosteric therapeutics using a proprietary discovery platform designed to identify functional pockets across multiple protein classes, with an internal focus on rare hematology.
BiotechHealthtechMedical Devices
Bryan E. Stuart(Chief Executive Officer)inMarion Dorsch(President and Chief Scientific Officer)inJared Rutter(Founder)John Tallarico(Founder)Ralph DeBerardinis(Founder)
Co-investorsLux CapitalThe Column GroupNextech Invest
Avalanche Energy develops compact fusion technology to generate high-energy neutrons for materials testing, radioisotope production, and advanced nuclear battery systems serving defense, space, and commercial power applications.
Deep TechDefense TechEnergyRichland, US
Robin Langtry(Co-Founder, CEO)inBrian Riordan(Co-Founder, COO)in
BoardMatthew Nordan(Director)inKyle Teamey(Director)
Co-investorsCongruent VenturesFounders FundLowercarbon CapitalToyota VenturesAlumni VenturesAutodesk Foundation+6 more
Bia is a technology-driven electricity retailer in Colombia that lets businesses switch their energy provider and replace traditional meters with its proprietary BiaMonitor smart meter.
CleantechEnergyIoTBogota, CO
Sebastian Ruales(Founder)inGuillermo Plaza Roche(Director)Leonardo Velazquez Florez(Director)Juan Sebastian Ruales Duque(Director)Jaime E. Zunzunegui(Director)in
BoardNicolas Berman(Director)in
Co-investorsBBVA SPARKIDB LabKaszek VenturesMarathon VenturesNazcaNorte Ventures+4 more
Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.
BiotechHealthtechSan Diego, US
Vijaya Pattabiraman(Co-founder & Chief Technology Officer)inJeffrey Bode(Scientific co-founder)inFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)
Co-investorsJohnson & Johnson Innovation – JJDCVersant VenturesVenrockAlexandriaBlackRockFidelity Investments+2 more
Capacity Bio is a biotechnology company developing mitophagy modulators — small molecules, peptides, and nanoparticles that target mitochondrial biology to identify and clear dysfunctional mitochondria.
BiotechDeep TechLongevityPalo Alto, US
Amy Wang(PhD)inKenneth Horne(Executive Officer, Director)inDylan Morris(Director)inCristina Ghenoiu(Director)in
BoardTaro Inaba(Director)in
Co-investorsRemiges Ventures, Inc.Insight PartnersAN Venture PartnersRDiscovery
CDR-Life is a biotech company developing antibody-based therapeutics, with a focus on its proprietary platform and clinical pipeline.
AI & Machine LearningBiotechHealthtechHorgen, CH
Rouven Bingel-Erlenmeyer(Founder)inChristian Leisner(Co-founder)inDominik Escher(Co-founder)
Co-investorsJeito Capital
Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform.
BiotechDeep TechMedical Devices
George Kassiotis(Co-founder)Drew Pardoll(Co-founder)Houman Ashrafian(Co-founder)in
Co-investorsSamsara BioCapitalSV Health InvestorsPfizer VenturesDementia Discovery FundM VenturesPfizer Venture Investments
Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases.
BiotechHealthtechMedical DevicesSuzhou, CN
Co-investorsLAVLilly Asia VenturesOrbiMedPivotal Life SciencesExome Asset ManagementJanus Henderson Investors+3 more
Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins.
BiotechDeep TechMedical DevicesBurlington, US
KLEEM CHAUDHARY(Executive Officer, Director, Promoter)inKu-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)Kleem Chaudhary, PhD(President & CEO)
BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)inLAURA TADVALKAR(Director)in
Co-investorsDroia VenturesEisai Innovation, Inc.Novartis Venture Fund
Indapta Therapeutics develops an off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy derived from healthy donors to treat cancer and autoimmune diseases.
BiotechHealthtechHouston, US
Guy DiPierro(Chief Operating Officer & Co-Founder)inSungjin Kim(Scientific Founder)John Sunwoo(Scientific Founder)Mark W. Frohlich(Chief Executive Officer)Stefanie Mandl-Cashman(Acting Chief Scientific Officer)
Co-investorsLeaps by BayerVertex Ventures HC
Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.
BiotechHealthtechMedfield, US
Roger Heerman(Chief Business/Operating Officer / Co-Founder)inFrazer Morgan(Chief Development Officer / Co-Founder)inRobert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)
BoardJamil Beg(Director of the Issuer)inTom King(Director of the Issuer)
Co-investors5AM VenturesAtlas VentureEQT Life SciencesGimvSixty Degree CapitalVivo Capital+3 more
MMI develops miniaturized robotic surgical instruments and platforms to enable surgeons to perform complex microsurgery and supermicrosurgery on delicate anatomical structures with greater precision.
HealthtechMedical DevicesRoboticsJacksonville, US
Mark Toland(Executive Officer, Director)inAndrew Cleeland(Director)Justin Lynch(Director)inTheresa Jean Cameron(Director)Caleb Moore(Executive Officer)Augusto Vianna Castello(Director)
Co-investorsAndera PartnersBioStar CapitalDeerfield Management CompanyFidelity InvestmentsCorewell Health VenturesFountain Healthcare Partners
PAhR Therapeutics is a clinical-stage biotech company developing novel mechanisms to treat pulmonary arterial hypertension (PAH).
BiotechHealthtech
Co-investorsAN Venture PartnersUTEC
Pluton is developing a sun-powered, soil-surface biological nutrient system that uses photosynthetic microbial consortia to fix atmospheric nitrogen, improve phosphorus availability, and add carbon to soil for crop growers.
AgTechBiotechClimate TechSt. Louis, US
Barry Goldman(Co-founder)inElizabeth Gallegos(Chief Executive Officer)inJerry Steiner(Executive Chair)inCharlie Walch(Executive Officer, Director)inGlendon Schuster(Director)
Co-investorsFirst In VenturesIllumina VenturesRadicle GrowthFall Line CapitalGrantham FoundationThe Yield Lab+3 more
Sydnexis is a privately held biopharmaceutical company developing SYD-101, a proprietary low-dose atropine formulation in Phase 3 clinical trials to slow the progression of pediatric progressive myopia.
BiotechDigital HealthDel Mar, US
Patrick Johnson(Executive Officer, Promoter)inMary Jaqueline Johnson(Executive Officer)Mary Jacqueline Johnson(Executive Officer)Kevin Johnson(Director)Greg Ostrow(Executive Officer, Director)Kenneth Widder(Executive Officer, Director)
Co-investorsLongitude CapitalVisionary Ventures
Synolo Therapeutics develops conditionally-active immunotherapies for treating cancer, using a proprietary discovery platform to build a pipeline of oncology drug candidates.
BiotechHealthtech
TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.
BiotechDeep TechHealthtechLexington, US
Patrick Trojer(President & Chief Executive Officer)in
Co-investorsAscenta CapitalAtlas VentureLightspeed Venture PartnersBessemer Venture PartnersPfizer VenturesFinchley Healthcare Ventures+3 more
Vivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types.
BiotechHealthtechMedical DevicesSan Mateo, US
Shuang Qiao(Executive Officer, Director)Sheng Ding(Executive Officer)Sofie Qiao(Founder)
BoardEdward Hu(Director)Jun Wu(Director)Jake Simson(Director)in
Co-investorsCanaan PartnersCenova CapitalMission Biocapital
Voro Metals operates a patent-pending pyrometallurgical process that removes residual copper and other contaminant metals from recycled scrap steel, upgrading low-grade feedstock into higher-value material.
Circular EconomyCleantechNew Materials
Acrivon is a clinical-stage oncology company developing precision medicine therapeutics for cancer treatment, using its proprietary AP3 proteomics platform to create companion diagnostics that match patients to drugs based on tumor-driving mechanisms.
AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US
Peter Blume-Jensen(Executive Officer, Director)Kristina Masson(Executive Officer, Director)erick gamelininEric Devroe(Executive Officer)in
BoardMarcin Czernik(Director)Sharon Shacham(Director)
Board seatDerek DiRocco· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)Pureos BioventuresWellington Management
ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.
BiotechHealthtechMedical DevicesSan Diego, US
Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)
BoardJonathan Leff(Director)
Board seatPeter Kolchinsky· per SEC Form D
Co-investorsNextech InvestOrbiMedSR One Capital ManagementSofinnova Ventures
Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings.
BiotechHealthtechMedical DevicesSan Diego, US
Jennifer Bush(Executive Officer)inThomas J. Farrell(Executive Officer)Fred Aslan(Executive Officer, Director)inJason Litten(Executive Officer)inEsther van den Boom(Executive Officer)Peter Flynn(Executive Officer)in
Board seatLaura Stoppel· per SEC Form D
Co-investors5AM VenturesEcoR1 CapitalvenBio PartnersWellington ManagementvenBio Global Strategic
Convergent Therapeutics develops radioantibody-based (PSMA-targeted) therapies for cancers, including metastatic castration-resistant prostate cancer (mCRPC).
BiotechHealthtechCambridge, US
Philip Kantoff(Chief Executive Officer, Co-Founder)inNeil Bander(Senior Scientific Advisor, Co-Founder)Alexander Brown(Executive Officer)inAndrew Davis(Chief Business and Strategy Officer)inElizabeth L. Montgomery(Chief People Officer)inEric M. Sullivan(Chief Financial Officer)in
Board seatJake Simson· per SEC Form D
Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.
BiotechHealthtechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)
BoardMichael Gladstone(Director)inJulie Papanek Grant(Director)inJohn Josey(Director)inDaniel Becker(Director)
Board seatDerek DiRocco· per SEC Form D · $130M raise · filed Feb 2021
Co-investorsAccess BiotechnologyAtlas VentureCanaan PartnersViking GlobalAccess IndustriesThe Column Group
Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief.
BiotechHealthtechPalo Alto, US
Luis Pena(President & Chief Executive Officer)inJanice Drew(Executive Officer)David Cohen(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)Francois Beaubien(Director)
Board seatDerek DiRocco· per SEC Form D
Co-investorsAndera PartnersAvego BioScience CapitalB Capital GroupB4 CapitalBeiersdorf Innovation FundFemHealth Ventures+4 more
.jpeg){kind=logo}
G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.
BiotechResearch Triangle Park, US
Jay Strum(Executive Officer)Norman Sharpless(Director)Mark A. Velleca(Executive Officer, Director)inThomas K Laundon(Executive Officer)Timothy Sullivan(Director)Gregory Mossinghoff(Executive Officer)
Board seatPeter Kolchinsky· per SEC Form D
Co-investorsLumira VenturesMountain Group CapitalSolasta VenturesHatteras Venture Partners
Vaccine development platform using computationally designed synthetic virus-like particles
BiotechSeattle, US
Charles Richardson(Senior Vice President, Technical Operations)Adam K. Simpson(President and Chief Executive Officer)Niranjan Kanesa-thasan(Chief Medical Officer)Douglas A. Holtzman(Chief Scientific Officer and Secretary)Cassia Cearley(Treasurer, Chief Business Officer)
Board seatPeter Kolchinsky· per SEC Form D
Co-investorsQiming Venture Partners USASanofi VenturesViking GlobalQiming HealthcareQiming Venture Partners
Rivus Pharmaceuticals develops mitochondrial-targeted therapies to treat cardiometabolic diseases.
BiotechDigital HealthHealthtechMedical DevicesCharlottesville, US
Francisco Portell(Co-founder & Vice President, Pharmaceutical Development)Allen Cunningham(Co-founder & Chief Operating Officer)inNancy Hargreaves(Executive Officer)Jayson Dallas(Executive Officer, Director)inShaharyar Khan(Co-founder & Chief Scientific Officer)in
BoardFrancesco De Rubertis(Director)in
Board seatDerek DiRocco· per SEC Form D · $57M raise · filed Jan 2025
Co-investorsMedicxiBain Capital Life SciencesLongitude Capital
Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.
AI & Machine LearningBiotechDeep TechSouth San Francisco, US
Robert Lefkowitz(Founder)Arthur Christopoulos(Founder)Patrick Sexton(Founder)Ran Xiao(Executive Officer)inElizabeth Bhatt(Executive Officer)Samira Shaikhly(Executive Officer)in
Board seatJake Simson· per SEC Form D
Co-investorsCatalio Capital Management, LPSamsara BioCapitalVertex Ventures HCThird Rock Ventures
Uses ML and big data to accelerate drug development.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesWaltham, US
Ajay Yekkirala, PhD(Founder)inRyan Bloom(Founder)inCATHERINE RIESEN(Executive Officer)CONY D'CRUZ(Executive Officer, Director, Promoter)inCRAIG RANDALL(Executive Officer)Ajay Yekkirala(Founder)
Board seatNandita ShangariAndrew Levin· per SEC Form D
Co-investorsGaingelsInsight PartnersNVenturesNVIDIA
__Twitter.png)
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.
BiotechHealthtechMedical DevicesWatertown, US
Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))inDavid Cordo(Executive Officer)Alon Lazarus(Director)
BoardChristoph Westphal(Director)Briggs Morrison(Director)in
Board seatDerek DiRocco· per SEC Form D
Co-investorsDC Investment PartnersK2 HealthVenturesLongwood FundMPM BioImpactTaiho Ventures, LLC
A clinical-stage biopharmaceutical company developing investigational therapies for patients with liver and cardiometabolic diseases, with a lead candidate (pegozafermin) being evaluated for metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.
BiotechHealthtechMedical DevicesSan Francisco, US
Rohan Palekar(Founder)in
Co-investorsK2 HealthVenturesLongitude Capital
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical Devices
Co-investorsVida VenturesHealthCapJeito CapitalNovo HoldingsOrbiMedPontifax Venture Capital+3 more
Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.
BiotechHealthtech
Co-investorsBain Capital Life SciencesSofinnova VenturesAtlas VentureForbion
Ajax Therapeutics is a biotech company developing Type II JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis, using computational chemistry and structural biology in its drug discovery.
AI & Machine LearningBiotechHealthtechNew York, US
Martin Vogelbaum(CEO, co-founder)inRoss Levine(Director)Ramy Farid(Director)
BoardScott Platshon(Director)
Co-investorsInning One VenturesEcoR1 CapitalRevelation PartnersVivo Capital
Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.
BiotechHealthtechBrookline, US
Emmanuel Simons(Executive Officer, Director)william sewell(Founder)in
BoardEd Mathers(Director)inKush Parmar(Director)in
Co-investors5AM VenturesEcoR1 CapitalNew Enterprise Associates (NEA)Pivotal Life SciencesSofinnova VenturesCowen Healthcare Investments+2 more
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)
Co-investorsAndreessen HorowitzAscenta CapitalDelos CapitalFrazier Life SciencesGeneral CatalystLightspeed Venture Partners+9 more
AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.
BiotechHealthtech
Co-investorsaMoonDelos CapitalBiotechnology Value FundSoleus Capital
AM Batteries develops Powder to Electrode dry coating technology for lithium-ion electrode manufacturing, reducing solvent use and energy consumption compared to traditional slurry methods.
Advanced ManufacturingCleantechEnergyMassachusetts, US
Yan Wang(Director)in
BoardAnil Achyuta(Director)inJimmy Kan(Director)inLisa Coca(Director)inLie Shi(Director)in
Co-investorsAnzu PartnersAsahi Kasei Corporate Venture CapitalCreative VenturesFoothill VenturesSAIC Technologies Fund II, LLCTDK Ventures+3 more
.jpeg){kind=logo}
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)inJosh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Co-investorsDroia VenturesInkefMission BiocapitalMRL Ventures FundNextech Invest
Ambros Therapeutics is a therapeutics company.
BiotechHealthtechSan Diego, US
Joseph (Jay) Hagan(President and Chief Executive Officer)
Co-investorsLifeSci Venture PartnersBAM ElevateJanus Henderson InvestorsPatient Square Capital
Angitia Bio is a biopharmaceutical company developing therapies for musculoskeletal and related diseases.
Biotech
Co-investorsAscenta CapitalFrazier Life SciencesOrbiMedWellington ManagementFrazier
Ansa provides an enzymatic DNA synthesis platform that directly synthesizes complex sequences up to 900 bp and delivers constructs up to 50 kb without assembly-based methods.
BiotechDeep TechHealthtechEmeryville, US
Dan Lin-Arlow(Founder)inSebastian Palluk(Founder)inDaniel Hillel Lin-Arlow(Executive Officer, Director)Jason T. Gammack(Executive Officer, Director)inDaniel Lin-Arlow(Founder)Jared Ellefson(Founder)
Co-investorsCarbon SiliconCerberus VenturesDauntless VenturesFifty YearsJude GomilaMetaplanet+12 more
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAltium CapitalAvego BioScience CapitalLifeSci Venture PartnersPontifax Venture CapitalAmzak Health+8 more
Apeiron is an NFT-based game featuring collectible planets, avatars, and apostles, with in-game elements, an arena, and a marketplace.
Crypto & Web3Gaming
Frank Cheng(Founder)
Co-investorsDigital Finance GroupHashedSkyVision CapitalS2G Investments
Apeiron Labs develops autonomous underwater vehicles and ocean technology for marine applications.
Climate TechDeep TechIoTRoboticsCambridge, US
Ravi Pappu(CEO / Board Member)in
BoardSanjeev Krishnan(Director)Jonathan Rosen(Director)David Douglas(Director)Kyle Teamey(Director)inMark Abbott(Director)
Co-investorsBay Bridge Ventures ClimateCoalitionS2G InvestmentsTFX CapitalBreakthrough Energy VenturesThe Engine Ventures
Arterial automates roadway asset inventory, inspection, and condition assessment by passively collecting data from vehicles already driving a network, detecting and ranking infrastructure problems like potholes for public agencies.
AI & Machine LearningConstruction TechData & InfrastructureGovTechMobility & TransportationBoulder, US
Co-investorsTechstarsAN Venture Partners
Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersDementia Discovery FundM VenturesNovartis Venture FundPfizer Venture InvestmentsSofinnova Partners+6 more
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.
BiotechHealthtechMedical DevicesDenmark, DK
Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)inGrethe Rasmussen(Executive Officer)inHarald Rau(Executive Officer)Martin Olin(Director)Lotte S?nderbjerg(Executive Officer)Martin Auster(Executive Officer)in
Co-investorsVivo CapitalAisling CapitalAvoro Capital AdvisorsForesite CapitalSofinnova PartnersSofinnova Ventures
Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.
BiotechHealthtechMedical DevicesSan Francisco, US
Ivana Djuretic(Founder)inAndy Yeung(Drug discovery)inYik Andy Yeung(Executive Officer, Director, Promoter)
Co-investorsEmles Venture PartnersGoAhead VenturesMission Bay CapitalMission BiocapitalWellington ManagementY Combinator+9 more
BiotechSan Francisco, US
Matthew Patterson(Executive Officer, Director)in
BoardJonathan Silverstein(Director)inSteve Squinto(Director)inKush Parmar(Director)inJonathan Leff(Director)Thomas Woiwode(Director)
Co-investorsAsset Management CompanyvenBio Partners5AM VenturesDeerfield Management CompanyOrbiMedVenrock
AusperBio is a Phase II clinical-stage biopharmaceutical company developing oligonucleotide (ASO) therapeutics, with a focus on curative treatments for hepatitis B (HBV).
BiotechHealthtech
Guofeng Cheng(Founder)in
Co-investorsQiming Venture Partners
Avalanche provides software development tools that startups can integrate to build and operate referral programs within their products.
Enterprise SoftwareMarketing TechSan Francisco, US
Elezhan (Ijan) Zhakiya(Founder)inNikhil Shinday
Co-investorsLowercarbon CapitalY Combinator8090 IndustriesCongruent VenturesFounders FundToyota Ventures
The Avalanche Foundation is a non-profit organization that supports innovation and growth in the Avalanche ecosystem through grants, programs, and strategic support for developers, entrepreneurs, and communities building on the Avalanche blockchain platform.
Crypto & Web3Data & InfrastructureDeveloper ToolsEnterprise SoftwareFintech
Emin Gun Sirer(Founder)inBrian Riordan(Founder)Elezhan (Ijan) Zhakiya(Founder)inEmin Gün Sirer(Founder)Kevin Sekniqi(Founder)Maofan Ted Yin(Founder)
Co-investorsa16z cryptoAegis VentuesAndreessen HorowitzAndromeda CapitalBaseTwoBig Brain Holdings+34 more
Ava Labs is a company building blockchain infrastructure and tools for creating and using finance applications.
Crypto & Web3Data & InfrastructureDeep TechFintechNew York City, US
Emin Gün Sirer(Founder)inEmin Gun Sirer(Founder)inCharley CooperinKevin Sekniqi(Founder)Maofan Ted Yin(Founder)Maofan Yin(Founder)
Co-investorsAnimoca BrandsAbstract VenturesCeras VenturesContinue CapitalInitialized CapitalLvna Capital+6 more
Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process.
BiotechWaltham, US
THERESA CAMERON(Director)MARTIN FREED(Director)inSTEPHANIE TOZZO(Executive Officer)PHIL GRAHAM(Executive Officer)MILIND DESHPANDE(Director)DAVID NEAFUS(Executive Officer)
Co-investorsAstellas Venture Management LLCMedical Excellence CapitalSanofi VenturesOpenSky Ventures
Azalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.
AI & Machine LearningBiotechMedical DevicesSan Francisco, US
Jennifer Doudna(Co-founder, Nobel Laureate in Chemistry and Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences, UC Berkeley)Rodolphe Barrangou(Co-founder, Associate Professor of Medicine, UCSF)Krishnendu Roy(Co-founder, Professor of Bioengineering, Stanford University)Connor Tsuchida(Scientific Cofounder)in
Co-investorsThird Rock VenturesSozo VenturesYosemite
Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.
BiotechLongevityMedical DevicesCambridge, US
David Meek(Chief Executive Officer)inBrian Riley(President & Chief Technical Officer)inJoanne Lager(Chief Medical Officer)inWendy DiCicco(Chief Financial Officer)inAdrian Chaisson(Chief of Staff)inJason Cole(Executive Officer)
Co-investorsARCH Venture PartnersEaston CapitalSanofi VenturesThink+ Ventures Management, LlcWakestream VenturesForbion+1 more
Bluejay is a biotechnology company focused on therapeutic development.
BiotechSan Mateo, US
Keting Chu(Founder, Chief Executive Officer and Chairman of the Board)inDajun Yang(Director)Nancy Hong(Director)inAlon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
Co-investorsFrazier Life SciencesRiverVest Venture PartnersWellington ManagementFrazier Healthcare PartnersHBM Healthcare InvestmentsNovo Holdings+2 more
Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.
BiotechHealthtechCambridge, US
Nick Lydon(Director)Christoph S. Lengauer(Executive Officer)inChristine Bellon(Executive Officer)inKyle Kuvalanka(Executive Officer)in
BoardAlexis Borisy(Executive Officer, Director)Daniel Lynch(Director)
Co-investorsF-Prime CapitalForesite CapitalNextech InvestRidgeback CapitalWellington ManagementThird Rock Ventures
Develops specialty products for orphan diseases and targeted cancers.
James Xue(Founder)
Co-investorsGeneral AtlanticQiming Venture Partners
AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.
BiotechHealthtechMedical DevicesSan Diego, US
Adrian Bot(Executive Officer)Laura Shawver(Executive Officer, Director)inRamin Farzaneh-Far(Executive Officer)inJustin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)
Co-investorsFinchley Healthcare VenturesPfizer Venture InvestmentsSofinnova VenturesVida VenturesAlexandriaForbion
Carmot is a clinical-stage biotechnology company developing novel treatments for obesity and type 2 diabetes through biased receptor agonist compounds.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechMedical DevicesBerkeley, US
Daniel A. Erlanson(Executive Officer, Director)Stig K. Hansen(Executive Officer, Director)Heather Turnerin
BoardTim Kutzkey(Director)Larry Lasky(Director)Aetna Wun Trombley(Director)
Co-investorsFrazier Life SciencesHorizons VenturesTCG CrossoverThe Column Group
Celea develops deupirfenidone, a pulmonary therapeutic targeting idiopathic pulmonary fibrosis in partnership with physicians and patient advocacy organizations.
BiotechHealthtechMedical Devices
Co-investorsPureTech HealthLeaps by Bayer
CellCentric develops inobrodib, a small-molecule oral p300/CBP inhibitor intended to treat multiple myeloma and other cancers.
BiotechHealthtechMedical Devices
Azim Surani(Co-founder)
Co-investorsAvego BioScience CapitalFuture Planet CapitalHBM Healthcare InvestmentsHBM PartnersSofinnova PartnersBrightEdge+3 more
Pharmaceutical company developing medicines and vaccines for patient health and treatment.
BiotechHealthtechSan Diego, US
Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)inKevin Forrest(Executive Officer)Dirk Thye(Executive Officer)inKen Bartizal(Executive Officer)inPaul Daruwala(Executive Officer)in
Co-investors5AM VenturesAisling CapitalBain Capital Life SciencesFrazier Life SciencesVivo CapitalCanaan Partners+1 more
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Matthew P. Jacobson(Co-founder)Scott R. Lokey(Director)David J. Earp(President & CEO)inPaul Park(Executive Officer)
BoardThilo Schroeder(Director)inWalter H. Moos(Director)
Co-investorsBerkeley CatalystHemisphere Ventures LLCJude GomilaLifeforce CapitalMission Bay CapitalMission Biocapital+4 more
BiotechChelsea, US
RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)inMARK IWICKI(Executive Officer, Director)inMARTIN FREED(Executive Officer)in
BoardROB HOPFNER(Director)in
Co-investorsCanaan PartnersLongitude CapitalSofinnova VenturesBay City CapitalFountain Healthcare PartnersOrbiMed
Claris Bio develops biologic therapies for sight-threatening eye diseases, with a current focus on bringing CSB-001, a novel treatment for patients with limbal stem cell deficiency, through clinical development and to market.
BiotechHealthtechMedical DevicesJersey City, US
Clarke Atwell(Co-Founder and Chief Operating Officer)inHenry Rath(Executive Officer)Susan Orr(Executive Officer)inStephen Brady(Executive Officer, Director)Michael Dybbs(Director)Matt Hobson(Director)
Co-investorsCatalio Capital Management, LPSofinnova VenturesCatalio Capital ManagementNovo HoldingsSamsara BioCapital
Climb is a French wealth management service that combines advisors with technology to grow clients' assets through an open-architecture selection of investment products (life insurance, retirement PER, real estate, private equity, tax-reduction schemes, crypto).
FintechSaaS
Aldric Emié(CEO)in
Co-investorsKima VenturesAlly Bridge GroupREDMILE
Commons produces CBD gummies marketed for relaxation and wellness purposes, sold direct-to-consumer through their online store.
ConsumerDirect to ConsumerWellness & Fitness
BoardTahira
Co-investorsEmles Venture PartnersCourtside VenturesFloating PointSteelSky VenturesTime BioVentures
Commons Clinic is an orthopedic care provider offering treatment for spine, joint, and sports medicine conditions, along with preventive health services such as full-body MRI and biomarker labs.
Digital HealthHealthtechWellness & FitnessAustin, US
Brad Hively(Director)inNick Aubin(Founder)inPaulo Marques Da Costa(Executive Officer, Director)Prithviraj Singha Roy(Director)in
BoardJohn Loser(Director)inDavid Berry(Director)in
Co-investorsCourtside VenturesFloating PointNorth South VenturesSteelSky VenturesTime BioVenturesAverin Capital+1 more
Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception.
BiotechDigital HealthMedical DevicesCharlottesville, US
Kevin Eisenfrats(Founder)inJohn Herr(Founder)
BoardIris Van Alderwerelt van Rosenburgh(Director)Gurdane Bhutani(Director)inMartin J Emerson(Director)Tom Thorpe(Director)
PartnerLaura Stoppel· quoted
Co-investorsBiotechnology Value FundMBX CapitalAllied Venture PartnersAlumni VenturesAmboy Street VenturesAurum Venture Partners+18 more
Convergent provides an AI simulation platform for enterprise training and skill development.
AI & Machine LearningEnterprise SoftwareHR TechSaaSLondon, GB
Co-investorsTechstarsAndreessen HorowitzOrbiMed
Develops therapies for cardiometabolic conditions.
Co-investorsNew Enterprise Associates (NEA)HBM Healthcare InvestmentsRTW Investments L.P.
Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.
BiotechHealthtech
George Simeon(CEO)inGregory S. Curhan(CFO)Guy De La Rosa(CMO)in
Co-investorsAdjuvant CapitalOrbiMedSanofi VenturesHBM Healthcare InvestmentsJanus Henderson InvestorsMedicxi
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.
BiotechHealthtechCambridge, US
Kevin Mills(Executive Officer, Director)inRonald Goldstein(Executive Officer)inDonald Corcoran(Executive Officer, Director)inMarkus Renschler(Director)in
BoardTimothy Romberger(Director)Barry Mills(Director)
Co-investorsDroia VenturesLightstone VenturesOUP (Osage University Partners)Shah Family OfficeAlly Bridge GroupDe Novo Ventures+3 more
DealForma provides a data platform and analyst support for biopharma business development teams to research partnerships, deals, funding trends, and therapeutic areas.
BiotechData & InfrastructureHealthtechSaaS
Chris
Co-investorsTinySeedAlgerREDMILERTW Investments L.P.Sofinnova Ventures
Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds.
BiotechDigital HealthMedical Devices
David Olson(Founder)David Olson Nick Haft(Founder)Nick Haft(Founder)
Co-investorsArtis VenturesBailey Venture PartnersCasa Verde CapitalDolby Family VenturesNoeticOMX Ventures+7 more
Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases.
AI & Machine LearningBiotechHealthtechWatertown, US
Alex Lugovskoy(Founder)Michael Gladstone(Founder)
Co-investorsAtlas VentureEcoR1 CapitalFrazier Life SciencesRV Invest GmbHSanofi VenturesViking Global
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
ADRxAerovate TherapeuticsAntera TherapeuticsCalimmuneDiCE MoleculesFreenome HoldingsLantos TechnologiesLonestar MedicinesMemento MedicinesNanoMosaicNature's ToolboxSojournixTypewriter TherapeuticsVaxess Technologies, Inc.AavantiBioAcumen PharmaceuticalsAdagio TxAlentisAliada TherapeuticsAmplifier TherapeuticsAperion LabsArcutis BiotherapeuticsArtiosArvinasAset TherapeuticsAveXisBellicum PharmaceuticalsBluejay TherapeuticsBraeburn PharmaceuticalscAMPfield TherapeuticsCerebral TherapeuticsClementiaClementiapharmaCoherusCollegiumConvergent TxConveyor TherapeuticsCortica CareCrineticsCytekDay OneDesign Therapeutics
Browse all 373 investments with full details →
▶173 more tracked companies
Diamond TherapeuticsDiceDicernaDicerna PharmaceuticalsDignify TherapeuticsDimensionDTx PharmaDyneDynelectroEdgewiseEidos TherapeuticsElectra TherapeuticsElektrofiElement BiosciencesEmergence TherapeuticsEmpaticaEverest MedicinesEvodia BioEvodiaBioExpansion TherapeuticsExpedition TherapeuticsEyconisFamiliar Machines & MagicFarcastForge BiologicsFormaForward TherapeuticsFrontier MedicinesGaleraGametoGentiBioGIVAXGlobal Blood TherapeuticsHaldaHalda TherapeuticsHemaBHilleVaxIDRxIDRXILiAD BiotechnologiesImbriaImbria PharmaceuticalsInfinimmuneInflaRxInhibikase TherapeuticsInhibrxInnoventricInozymeInterius BioInterius BioTherapeuticsIO BiotechiTeos TherapeuticsIvantis IncJade BioJanuxJnana TherapeuticsJunoKalvistaKaryopharm TherapeuticsKinnateKinnate BiopharmaKolomaLegend BioLenzLifeMineLifeMine TherapeuticsLumenaLusaris TherapeuticsLyraMagenta MedicalMarianaMariana OncologyMBXMerusMetagenomiMetseraMineralysMMIMMI MicroModernaNapiGenNavaNavigator MedicinesNew Equilibrium BiosciencesNexCureNextopNiKang TherapeuticsNimbusNimbusNimbus TherapeuticsNivalisNorthLinks BioNucleixObsidian TherapeuticsOcelot BioOlemaOllinOllin BiosciencesOncologyOptivoltOrchardPAhR TherapeuticsPandion TherapeuticsPharmaPhathomPinnacle MedicinesPlanted SolarPlantiblePluton BioPMV PharmaPoint BiopharmaPoplar TherapeuticsPrevailPrevail TherapeuticsProfound BioProtagonistQuellis BiosciencesRa PharmaceuticalsRadenceReframe SystemsRegulusRivus PharmaROME TherapeuticsSatsumaSatsuma PharmaceuticalsSeagenSecretome TherapeuticsSeLux Diagnostics, Inc.Serapha BioShockwaveSidera BioSierra OncologySilverback TherapeuticsSlate MedicinesSomatusSonoTheraSortera TechnologiesSparrow PharmaSpyreStar TherapeuticsStokeStylus MedicineSummation BioSynapticureSynthegoSynthekineSynthorxT-KnifeT2 BiosystemsTaris BiomedicalTassoTenayaTeraPore TechnologiesTerremoto BiosciencesterrestrialThriveworksTopl (Now Plasma)Torl BioTrace NeuroscienceTscanTScan TherapeuticsTyraVentus AIVentus TherapeuticsVerdiva BioVerve TherapeuticsViaCyteVilyaVitriVaxVividionWhiteSwellWindwardWindward Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 104
69 IPOs · 35 acquisitions · showing 77FreenomeNASDAQ: FRNMSionna TherapeuticsNASDAQ: SIONMineralys TherapeuticsNASDAQ: MLYSSpero TherapeuticsNASDAQ: SPROWave Life SciencesNASDAQ: WVEAclaris TherapeuticsNASDAQ: ACRSAdagio MedicalNASDAQ: ADGMAdagio Medical HoldingsNASDAQ: ADGMAdagio TherapeuticsNASDAQ: IVVDAeglea BiotherapeuticsNASDAQ: SYREAgenusNASDAQ: AGENAktis OncologyNASDAQ: AKTSAN2 TherapeuticsNASDAQ: ANTXApogee TherapeuticsNASDAQ: APGEArcutisNASDAQ: ARQTArvinas Holding Co. LLCNASDAQ: ARVNAtea PharmaceuticalsNASDAQ: AVIRBicara TherapeuticsNASDAQ: BCAXBioAge LabsNASDAQ: BIOABiohavenNYSE: BHVNBlack Diamond Therapeutics, IncNASDAQ: BDTXBolt BiotherapeuticsNASDAQ: BOLTBoundless BioNASDAQ: BOLDC4 TherapeuticsNASDAQ: CCCCCentury Therapeutics, Inc.NASDAQ: IPSCCeribellNASDAQ: CBLLCG OncologyNASDAQ: CGONClimb BioNASDAQ: CLYMCollegium PharmaceuticalNASDAQ: COLLConnect BiopharmaNASDAQ: CNTBCrinetics PharmaceuticalsNASDAQ: CRNXCytek BiosciencesNASDAQ: CTKBDamora TherapeuticsNASDAQ: DMRADesigntxNASDAQ: DSGNDiffusion PharmaceuticalsNASDAQ: CRVODyne TherapeuticsNASDAQ: DYNEliem TherapeuticsNASDAQ: CLYMEnliven TherapeuticsNASDAQ: ELVNGH ResearchNASDAQ: GHRSHemab TherapeuticsNASDAQ: COAGImaraNASDAQ: ELVNInvivydNASDAQ: IVVDKALA BIONASDAQ: KALAMonopar TherapeuticsNASDAQ: MNPRNateraNASDAQ: NTRANkarta, Inc.NASDAQ: NKTXOlema PharmaceuticalsNASDAQ: OLMAParabilis MedicinesNASDAQ: PBLSPelotonNASDAQ: PTONPepGenNASDAQ: PEPGPrecision BioSciencesNASDAQ: DTILProtagonist TherapeuticsNASDAQ: PTGXProthenaNASDAQ: PRTAPyxis OncologyNASDAQ: PYXSRani TherapeuticsNASDAQ: RANIRani Therapeutics HoldingsNASDAQ: RANIRelmada TherapeuticsNASDAQ: RLMDRxsightNASDAQ: RXSTScribe TherapeuticsNASDAQ: SCTXScynexisNASDAQ: SCYXSeres TherapeuticsNASDAQ: MCRBSolid BiosciencesNASDAQ: SLDBSpyglass PharmaNASDAQ: SGPSUTROVAX, INC.NASDAQ: PCVXTenaya TherapeuticsNASDAQ: TNYATYRA BiosciencesNASDAQ: TYRAVaxcyteNASDAQ: PCVXVor BiopharmaNASDAQ: VORXilio TherapeuticsNASDAQ: XLOAerovate Therapeuticsacq. by Jade BiosciencesCalimmuneacq. by CSL Behring89bio (NASDAQ: ETNB)acq. by RocheAliada Therapeuticsacq. by AbbVieAmbros Therapeuticsacq. by Werewolf TherapeuticsBellicum Pharmaceuticalsacq. by The University of Texas MD Anderson Cancer CenterBluejaytxacq. by Mirum PharmaceuticalsDay Oneacq. by Servier
Portfolio news
latest coverage across their companies
Black Diamond Therapeutics, Inc · finance.yahoo.com · Sep 2, 2026
Invivyd · investors.invivyd.com · Sep 1, 2026
Vaxcyte · manilatimes.net · Aug 27, 2026
InflaRx · manilatimes.net · Aug 20, 2026
Peloton · en.wikipedia.org · Aug 19, 2026
Abcuro · finsmes.com · Aug 18, 2026
Agenus · simplywall.st · Aug 15, 2026
IPO stake values · per SEC filings · 25
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Sionna Therapeutics | 21.9% | $18.00 | Feb 2025 | $167.8M |
| Eliem Therapeutics | 51.9% | $12.50 | Aug 2021 | $164.4M |
| Parabilis Medicines | 6.5% | $20.00 | Jun 2026 | $154.9M |
| Vor Biopharma | 22.2% | $18.00 | Feb 2021 | $142.2M |
| Apogee Therapeutics | 3.4% | $62.00 | Mar 2024 | $122.6M |
| Cytek Biosciences | 5.1% | $17.00 | Jul 2021 | $113.2M |
| TYRA Biosciences | 14.6% | $16.00 | Sep 2021 | $95.8M |
| Bicara Therapeutics | 9.9% | $18.00 | Sep 2024 | $92.2M |
| Hemab Therapeutics | 10.9% | $18.00 | May 2026 | $87.1M |
| Wave Life Sciences | 24.9% | $16.00 | Nov 2015 | $83.4M |
| Adagio Therapeutics | 4.4% | $17.00 | Aug 2021 | $81.6M |
| Invivyd | 4.4% | $17.00 | Aug 2021 | $81.6M |
| Dyne Therapeutics | 5.5% | $28.00 | Jan 2021 | $78.5M |
| Spyglass Pharma | 13.6% | $16.00 | Feb 2026 | $69.3M |
| AN2 Therapeutics | 19.6% | $15.00 | Mar 2022 | $55M |
| SUTROVAX, INC. | 6.2% | $16.00 | Jun 2020 | $47.8M |
| Vaxcyte | 6.2% | $16.00 | Jun 2020 | $47.8M |
| Bolt Biotherapeutics | 6.9% | $20.00 | Feb 2021 | $47.6M |
| Solid Biosciences | 7.8% | $16.00 | Jan 2018 | $43M |
| Prothena | 7.8% | $22.00 | Oct 2013 | $36.3M |
| Olema Pharmaceuticals | 4.5% | $19.00 | Nov 2020 | $32.8M |
| Collegium Pharmaceutical | 6.6% | $20.00 | Jan 2016 | $30.9M |
| Mineralys Therapeutics | 4.9% | $16.00 | Feb 2023 | $30.9M |
| Black Diamond Therapeutics, Inc | 4.6% | $19.00 | Jan 2020 | $30.2M |
| Boundless Bio | 8.4% | $16.00 | Mar 2024 | $29.9M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Dec 2018
Disclosed stake · filed Feb 2017
Disclosed stake · filed Feb 2017
Disclosed stake · filed Feb 2017
Disclosed stake · filed Feb 2017
Disclosed stake · filed Feb 2017
Disclosed stake · filed Feb 2017
Disclosed stake · filed Feb 2017
Disclosed stake · filed Feb 2017
450 insider ownership filings (Forms 3/4/5)
at Septerna, Inc. (SEPN), Inhibikase Therapeutics, Inc. (IKT), Artiva Biotherapeutics, Inc. (ARTV), Freenome, Inc. (FRNM), Parabilis Medicines, Inc. (PBLS), Vor Biopharma Inc. (VOR), Climb Bio, Inc. (CLYM), ARS Pharmaceuticals, Inc. (SPRY)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has RA Capital made?
- RA Capital has 373 tracked investments, 104 of which have exited, including 59 dated in the last 24 months.
- What stage does RA Capital invest at?
- RA Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does RA Capital focus on?
- RA Capital focuses on AgTech, Biotech, Cleantech, Climate Tech, Digital Health, Energy, Healthtech, Medical Devices.
- Where is RA Capital located?
- RA Capital is headquartered in Boston, US.
- Does RA Capital lead rounds?
- RA Capital has led 31 of the 82 rounds where its role is on record.
- Who does RA Capital co-invest with?
- RA Capital most often shares deals with Foresite Capital, Frazier Life Sciences, Wellington Management, among 356 tracked co-investors.
- What size deals does RA Capital back?
- Across 34 deals with disclosed amounts, RA Capital has joined rounds of $5M – $340M (median $91.8M).
Media · Podcasts & interviews
featuring the teamThe Investor's Paradox with Peter Kolchinsky, RA Capital
Incubate Coalition · Peter Kolchinsky
Images
Co-investors · 70
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Nextech Invest is a Zurich-based investor backing emerging biotechnology companies worldwide, focused on advancing precision medicine and transformative cancer therapies.
Bain Capital Life Sciences, founded in 2016, invests in biopharmaceutical, medical device, diagnostic, and life science tool companies globally, focusing on companies addressing unmet medical needs and driving medical innovation.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies aligned with Sanofi's mission of advancing human health.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Forbion is a global venture capital firm focused on advancing biotech innovations and other sustainable solutions aimed at improving human and planetary health.
Pivotal Life Sciences is a global healthcare investment firm backing companies developing high-impact therapeutics for major unmet medical needs, operating across venture capital, venture building, and public equity strategies.
▶58 more co-investors
Samsara BioCapitalThird Rock VenturesPfizer Venture InvestmentsAisling CapitalCanaan PartnersVenrockARCH Venture PartnersVersant VenturesSR One Capital Management5AM VenturesSV Health InvestorsRTW Investments L.P.F-Prime CapitalvenBio PartnersMRL Ventures FundPolaris PartnersThe Column GroupAndera PartnersJohnson & Johnson Innovation – JJDCNovartis Venture FundInsight PartnersKleiner PerkinsMPM BioImpactQiming Venture PartnersVertex Ventures HCRed Tree VentureArtis VenturesEQT Life SciencesRoche Venture FundGeneral CatalystCoatue ManagementNew Leaf Venture PartnersAnzu PartnersUS Venture PartnersTwo Sigma VenturesPlayground GlobalMithril Capital ManagementAccess IndustriesHatteras Venture PartnersYsios CapitalOmega FundsMedical Excellence CapitalHealthCapAbbVieHumboldtSignalFire23andMeBaruch Future VenturesPsyMed VenturesDe Novo VenturesQiming Venture Partners USAOverwater Ventures LlcUnknown VenturesAtomicoXtripe AngelsXSeed CapitalTencent HoldingsCofounders Capital
Firms observed investing alongside RA Capital, from public investor directories. Shared companies are the overlap with RA Capital's recorded portfolio.
Similar investors
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
MDI Ventures is the corporate venture capital arm of Indonesian telecommunications company Telkom Indonesia, investing in high-growth technology startups across Southeast Asia and globally, with a focus on creating synergies between portfolio companies and Telkom Group and Indonesian state-owned enterprises.
Seventure Partners is a European venture capital firm backing innovative companies across life sciences and digital technologies, with additional focus areas in sport & performance and the blue economy.